These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 10077182)

  • 21. Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group.
    Keefer MC; Wolff M; Gorse GJ; Graham BS; Corey L; Clements-Mann ML; Verani-Ketter N; Erb S; Smith CM; Belshe RB; Wagner LJ; McElrath MJ; Schwartz DH; Fast P
    AIDS Res Hum Retroviruses; 1997 Sep; 13(14):1163-77. PubMed ID: 9310283
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incentives and disincentives to participate in prophylactic HIV vaccine research.
    Jenkins RA; Temoshok LR; Virochsiri K
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 May; 9(1):36-42. PubMed ID: 7712233
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV gp120 vaccine - VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine - Genentech, HIV gp120 vaccine AIDSVAX - VaxGen, HIV vaccine AIDSVAX - VaxGen.
    Adis International Ltd
    Drugs R D; 2003; 4(4):249-53. PubMed ID: 12848591
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Issues in women's participation in a phase III community HIV vaccine trial in Thailand.
    Kaewkungwal J; Pitisuttithum P; Rerks-Ngarm S; Nitayaphan S; Khamboonruang C; Kunasol P; Suntharasamai P; Pungpak S; Vanijanonta S; Bussaratid V; Maek-A-Nantawat W; Dhitavat J; Thongcharoen P; Pawarana R; Sabmee Y; Benenson MW; Morgan P; O'Connell RJ; Kim J
    AIDS Res Hum Retroviruses; 2013 Nov; 29(11):1524-34. PubMed ID: 23343395
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Feasibility and suitability of targeting young gay men for HIV vaccine efficacy trials.
    Scheer S; Douglas JM; Vittinghoff E; Bartholow BN; McKirnan D; Judson FN; MacQueen KM; Buchbinder S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Feb; 20(2):172-8. PubMed ID: 10048905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lack of increased HIV risk behavior among injection drug users participating in the AIDSVAX B/E HIV vaccine trial in Bangkok, Thailand.
    van Griensvan F; Keawkungwal J; Tappero JW; Sangkum U; Pitisuttithum P; Vanichseni S; Suntharasamai P; Orelind K; Gee C; Choopanya K;
    AIDS; 2004 Jan; 18(2):295-301. PubMed ID: 15075548
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative thais.AFRIMS-RIHES Vaccine Evaluation Group. Armed Forces Research Institute of Medical Sciences and the Research Institute for Health Sciences.
    Nitayaphan S; Khamboonruang C; Sirisophana N; Morgan P; Chiu J; Duliege AM; Chuenchitra C; Supapongse T; Rungruengthanakit K; deSouza M; Mascola JR; Boggio K; Ratto-Kim S; Markowitz LE; Birx D; Suriyanon V; McNeil JG; Brown AE; Michael RA
    Vaccine; 2000 Feb; 18(15):1448-55. PubMed ID: 10618542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Personal experiences following acquiring HIV infection while volunteering in Phase I/II HIV vaccine trials: A qualitative study from Tanzania.
    Tarimo EAM; Ambikile J; Munseri P; Bakari M
    PLoS One; 2022; 17(10):e0276404. PubMed ID: 36288332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recruitment, screening and characteristics of injection drug users participating in the AIDSVAX B/E HIV vaccine trial, Bangkok, Thailand.
    Vanichseni S; Tappero JW; Pitisuttithum P; Kitayaporn D; Mastro TD; Vimutisunthorn E; van Griensvan F; Heyward WL; Francis DP; Choopanya K;
    AIDS; 2004 Jan; 18(2):311-6. PubMed ID: 15075550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E.
    Rerks-Ngarm S; Paris RM; Chunsutthiwat S; Premsri N; Namwat C; Bowonwatanuwong C; Li SS; Kaewkungkal J; Trichavaroj R; Churikanont N; de Souza MS; Andrews C; Francis D; Adams E; Flores J; Gurunathan S; Tartaglia J; O'Connell RJ; Eamsila C; Nitayaphan S; Ngauy V; Thongcharoen P; Kunasol P; Michael NL; Robb ML; Gilbert PB; Kim JH
    J Infect Dis; 2013 Apr; 207(8):1195-205. PubMed ID: 22837492
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Social Impacts Among Participants in HIV Vaccine Trial Network (HVTN) Preventive HIV Vaccine Trials.
    Andrasik MP; Sesay FA; Isaacs A; Oseso L; Allen M
    J Acquir Immune Defic Syndr; 2020 Aug; 84(5):488-496. PubMed ID: 32692107
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Screening and evaluation of potential volunteers for a phase III trial in Thailand of a candidate preventive HIV vaccine (RV148).
    Ministry of Public Health-Thai AIDS Vaccine Evaluation Group
    Vaccine; 2011 Jun; 29(25):4285-92. PubMed ID: 21435408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic vaccine trails in Thailand.
    Churdboonchart V
    J HIV Ther; 2004 Sep; 9(3):57-9. PubMed ID: 15534562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV vaccines: the Uganda experience.
    Mugyenyi PN
    Vaccine; 2002 May; 20(15):1905-8. PubMed ID: 11983242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Community heroes or "high-risk" pariahs? Reasons for declining to enroll in an HIV vaccine trial.
    Newman PA; Daley A; Halpenny R; Loutfy M
    Vaccine; 2008 Feb; 26(8):1091-7. PubMed ID: 18237829
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reported willingness to participate in a hypothetical HIV vaccine trial and its translation to actual participation among healthy adults-Experience from Kenya.
    Nyasani DK; Mutua GN; Sajabi RM; Ng'ang'a JW; Gachie JN; Maina AM; Lusike LL; Anzala AO; Price MA; Manyonyi GO
    PLoS One; 2018; 13(11):e0206656. PubMed ID: 30388145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug use and the risk of HIV infection amongst injection drug users participating in an HIV vaccine trial in Bangkok, 1999-2003.
    Martin M; Vanichseni S; Suntharasamai P; Mock PA; van Griensven F; Pitisuttithum P; Tappero JW; Chiamwongpaet S; Sangkum U; Kitayaporn D; Gurwith M; Choopanya K;
    Int J Drug Policy; 2010 Jul; 21(4):296-301. PubMed ID: 20079620
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV-1 risk and vaccine acceptability in the Ugandan military.
    Hom DL; Johnson JL; Mugyenyi P; Byaruhanga R; Kityo C; Louglin A; Svilar GM; Vjecha M; Mugerwa RD; Ellner JJ
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Aug; 15(5):375-80. PubMed ID: 9342258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. International clinical trials of HIV vaccines: II. phase I trial of an HIV-1 synthetic peptide vaccine evaluating an accelerated immunization schedule in Yunnan, China.
    Li D; Forrest BD; Li Z; Xue P; Hanson CV; Duan S; Cheng H; Li M; Wang CY; Koff WC
    Asian Pac J Allergy Immunol; 1997 Jun; 15(2):105-13. PubMed ID: 9346275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Social impact of preventive HIV vaccine clinical trial participation: a model of prevention, assessment and intervention.
    Allen M; Lau CY
    Soc Sci Med; 2008 Feb; 66(4):945-51. PubMed ID: 18162272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.